N-905
Nordiazepam solution
1 mg/mL in methanol, ampule of 1 mL, certified reference material, Cerilliant®
Se connecterpour consulter vos tarifs contractuels et ceux de votre entreprise/organisme
About This Item
Produits recommandés
Qualité
certified reference material
Forme
liquid
Conditionnement
ampule of 1 mL
Fabricant/nom de marque
Cerilliant®
drug control
Narcotic Licence Schedule B (Switzerland); psicótropo (Spain); Decreto Lei 15/93: Tabela IV (Portugal)
Concentration
1 mg/mL in methanol
Technique(s)
gas chromatography (GC): suitable
liquid chromatography (LC): suitable
Application(s)
clinical testing
Format
single component solution
Température de stockage
−20°C
Chaîne SMILES
Clc1ccc2NC(=O)CN=C(c3ccccc3)c2c1
InChI
1S/C15H11ClN2O/c16-11-6-7-13-12(8-11)15(17-9-14(19)18-13)10-4-2-1-3-5-10/h1-8H,9H2,(H,18,19)
Clé InChI
AKPLHCDWDRPJGD-UHFFFAOYSA-N
Description générale
Nordiazepam is a benzodiazepine prescribed for treatment of anxiety and panic attacks. This analytical reference standard is suitable for use in LC/MS or GC/MS applications for clinical toxicology, forensic analysis, or urine drug testing applications. Nordiazepam is also a primary urinary metabolite of benzodiazepines diazepam and chlrodiazepoxide.
Application
- Probe Electrospray Ionization Tandem Mass Spectrometry for the Detection and Quantification of Benzodiazepines: This study employs advanced mass spectrometry techniques to enhance the detection and quantification of Nordiazepam and other benzodiazepines, critical for therapeutic drug monitoring in clinical settings. This method ensures high sensitivity and specificity, improving pharmacokinetic studies of benzodiazepine metabolites (Griffeuille et al., 2024).
- Selective Extraction of Diazepam and Its Metabolites from Urine Samples: Details a molecularly imprinted solid-phase extraction method, utilizing analytical grade Nordiazepam for benchmarking, to selectively extract diazepam and its metabolites from urine. This approach is pivotal for forensic and clinical toxicology, providing a reliable method for drug monitoring and abuse detection (Gil Tejedor et al., 2024).
- Hair Analysis in Postmortem Investigations: Discusses the application of hair analysis in forensic science, where Nordiazepam and other drug residues are identified in postmortem samples. This technique is essential for determining drug involvement in unexplained deaths, offering insights into chronic drug use or poisoning (Pelissier-Alicot et al., 2024).
- Diazepam: A comprehensive review of diazepam, detailing its pharmacology, therapeutic use, and metabolism, including Nordiazepam as a significant metabolite. This information is crucial for healthcare professionals to understand the effects, interactions, and potential side effects of this widely used benzodiazepine (2006).
- Trace Analysis of Psychotropic Medications in Environmental Samples: Utilizes ultra-performance liquid chromatography tandem mass spectrometry (UPLC-MS/MS) to detect low concentrations of Nordiazepam and other psychotropic medications in environmental samples. This research supports environmental health studies by tracking pharmaceutical pollutants, which can affect water sources and wildlife (Wang et al., 2024).
Produits recommandés
Find a digital Reference Material for this product available on our online platform ChemisTwin® for NMR. You can use this digital equivalent on ChemisTwin® for your sample identity confirmation and compound quantification (with digital external standard). An NMR spectrum of this substance can be viewed and an online comparison against your sample can be performed with a few mouseclicks. Learn more here and start your free trial.
Informations légales
CERILLIANT is a registered trademark of Merck KGaA, Darmstadt, Germany
Produit(s) apparenté(s)
Réf. du produit
Description
Tarif
Mention d'avertissement
Danger
Mentions de danger
Conseils de prudence
Classification des risques
Acute Tox. 3 Dermal - Acute Tox. 3 Inhalation - Acute Tox. 3 Oral - Flam. Liq. 2 - STOT SE 1
Organes cibles
Eyes,Central nervous system
Code de la classe de stockage
3 - Flammable liquids
Classe de danger pour l'eau (WGK)
WGK 2
Point d'éclair (°F)
49.5 °F - closed cup
Point d'éclair (°C)
9.7 °C - closed cup
Certificats d'analyse (COA)
Recherchez un Certificats d'analyse (COA) en saisissant le numéro de lot du produit. Les numéros de lot figurent sur l'étiquette du produit après les mots "Lot" ou "Batch".
Déjà en possession de ce produit ?
Retrouvez la documentation relative aux produits que vous avez récemment achetés dans la Bibliothèque de documents.
Les clients ont également consulté
Craig Lehmann et al.
Journal of clinical pharmacology, 48(4), 436-444 (2008-02-02)
A diazepam 10-mg autoinjector was evaluated in bioequivalence and dose proportionality studies; both involved 24 young, healthy subjects and used randomized, open-label, 2-treatment, 2-period crossover designs with a 3-week washout period between treatments. The bioequivalence study compared a single diazepam
Shanlin Fu et al.
Journal of analytical toxicology, 34(5), 243-251 (2010-06-10)
beta-Glucuronidase is an enzyme often employed to de-conjugate beta-glucuronides during urinary drug testing for benzodiazepines. It is commonly accepted that use of beta-glucuronidase is a preferred method of hydrolysis over acid-catalyzed hydrolysis, which is known to induce benzodiazepine degradation and
David A Fishbain et al.
Pain medicine (Malden, Mass.), 10(3), 565-572 (2008-11-11)
The objectives of this medicolegal case report are the following: 1) to present details of a chronic pain patient (CPP) who was placed on chronic opioid analgesic therapy (COAT), and subsequently overdosed on multiple drugs, some of which were not
Ali Acikgöz et al.
Toxicology and applied pharmacology, 234(2), 179-191 (2008-11-06)
Drug biotransformation is one of the most important parameters of preclinical screening tests for the registration of new drug candidates. Conventional existing tests rely on nonhuman models which deliver an incomplete metabolic profile of drugs due to the lack of
Joris C Verster et al.
Sleep medicine reviews, 17(2), 153-159 (2012-08-14)
The use of benzodiazepine receptor agonists can significantly impair driving performance. The aim of this review was to determine if there is a relation between blood concentrations of these drugs and the degree of driving impairment. A literature search was
Notre équipe de scientifiques dispose d'une expérience dans tous les secteurs de la recherche, notamment en sciences de la vie, science des matériaux, synthèse chimique, chromatographie, analyse et dans de nombreux autres domaines..
Contacter notre Service technique